Business Wire

Sinocare Group Closes Acquisition of Nipro Diagnostics

7.1.2016 17:26 | Business Wire

Del

Nipro Diagnostics announced today that its acquisition by Sinocare Group has been completed. The company also announced that with completion of the acquisition, the company has been renamed Trividia Health. Scott Verner, who was Chairman, CEO and President of Nipro Diagnostics, has been named CEO and President of Trividia Health and will be joined by key executives from his current management team. The company will remain in the United States.

“Like Sinocare, Nipro Diagnostics has the long-term vision of being a leading global health and wellness company that offers innovative, high-value solutions so patients can live healthier lives,” Sinocare Chairman and CEO Shaobo Li said. “We have a great deal of respect for what the management team and employees have accomplished at Nipro Diagnostics, and we are confident in their ability to accelerate our shared vision. Joined together, our proven portfolio of products and services, our combined future direction and our strong confidence in the people who design, manufacture and sell our products and services, will be vital to attaining our shared goals.”

“Our company has experienced strong growth as a result of our new product launch cadence and our investments in highly sophisticated manufacturing and distribution facilities in the United States. This is an exciting next chapter for our combined company. I’m proud to have led the company through many changes in the public and private markets. I look forward to maximizing the global potential of our portfolio of solutions for patients, healthcare providers and our customers,” said Trividia Health CEO Scott Verner.

The new name, Trividia Health, signals the company’s new trajectory and represents the values, vision and market of the global enterprise. “TRI” honors Sinocare’s three commitments to customers, employees and shareholders; “VI” stands for the commitment to patient victory over diabetes and other health challenges; and “DIA” refers to the company’s core diabetes foundation. Finally, HEALTH was added to the name to signal the company’s new focus on developing integrated health solutions beyond diabetes.

About Trividia Health

Trividia Health, Inc., a wholly owned subsidiary of Sinocare Group, is a global health and wellness company based in Fort Lauderdale, Florida and a leading developer, manufacturer and marketer of advanced performance products for people with diabetes. With products sold under TRUE and store brand labels, the company is the exclusive partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world’s leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com.

About Sinocare Group

Sinocare Group consists of Sinocare, Inc., Sinocare Jianheng Diabetes Hospital, and its affiliates. Sinocare Inc., headquartered in Changsha, China, is fully dedicated to the innovation of biosensor technology, promoting diabetic self-management by using blood glucose monitoring systems, providing total diabetes services and solutions in China. Founded in 2002 and listed on the Shenzhen Stock Exchange (SHE:300298) in 2012, the company has been providing high quality and low cost blood glucose monitoring systems to the Chinese market and has been listed by Forbes as one of Asia's 200 Best Under a Billion companies.

Contact information

Trividia Health
Neal Bhattacharya, 1-800-342-7226 ext. 3150
nbhattacharya@niprodiagnostics.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00Pressemelding

Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and

Permasteelisa Group to Join Grandland21.8.2017 04:11Pressemelding

Worldwide leading contractor in engineering, project management, manufacturing and installation of architectural envelopes and interior systems, Permasteelisa Group, will join forces with Grandland Group – a fast growing, Shenzhen-based specialist in design and construction of architectural decoration. The strategic alliance will create the biggest, most comprehensive curtain wall player in the world, with exceptional potential for further growth for both companies. Permasteelisa will remain fully committed to build avant-garde architectures and top end, high-quality projects which have become its trademark. The news comes today after LIXIL Group Corporation (LIXIL Group) (TOKYO: 5938) – a global leader in the housing and building industry – announced that it has decided to sell 100% of shares of Permasteelisa S.p.A., held by its major subsidiary LIXIL Corporation, to Grandland Holding

LIXIL to Sell Permasteelisa to Grandland21.8.2017 03:42Pressemelding

LIXIL Group Corporation (LIXIL Group) (TOKYO:5938), a global leader in the housing and building industry, today announced that it has decided to sell 100% of the shares of Permasteelisa S.p.A (Permasteelisa) held by its major subsidiary LIXIL Corporation to Grandland Holdings Group Limited (Grandland), a leading Chinese architectural design and construction company. The transaction is subject to customary closing conditions and regulatory approvals, including in China, the United States and Russia. Under the terms of the agreement, the base sale price for Permasteelisa is EURO 467 million. As a result of this transaction and the deconsolidation of Permasteelisa from LIXIL Group, LIXIL Group’s revenue for the full fiscal year ending March 2018 is expected to decrease by approximately 170.0 billion yen from the amount announced on May 8, 2017 (by approximately 9.2% of the previously fore

Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies20.8.2017 23:30Pressemelding

Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170820005028/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) “Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” said Christopher Hansung Ko, President and CEO, Samsung Bioepis. “Five years ago, we entered

The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30Pressemelding

The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat

Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22Pressemelding

Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom